Combining the immune-boosting peptide thymosin α1 with antiviral drugs shows promise for achieving functional cure of chronic hepatitis B by attacking the virus from both sides.
Tα1 can eliminate HBsAg and HBeAg in select patientsWhen combined with highly effective antivirals, thymosin α1's immune-boosting effects may help clear viral markers that antiviral drugs alone cannot eliminate, potentially achieving functional cure.
What the researchers found
Combining thymosin α1 (Tα1), an immune-boosting peptide, with nucleos(t)ide analog antivirals (NUCs) may be more effective at clearing chronic hepatitis B than either approach alone. While NUCs suppress viral replication and Tα1 can help eliminate viral surface markers (HBsAg and HBeAg) in select patients, the combination leverages both viral suppression and immune activation. Small studies using Tα1 with NUCs showed encouraging results, and clinical trials combining entecavir with Tα1 were underway at the time of publication.
Why it matters
Chronic hepatitis B infects hundreds of millions of people worldwide, and current antiviral treatments suppress the virus but rarely cure it. A functional cure requires the immune system to clear remaining virus — exactly what thymosin α1 aims to do. This review makes the case that combining immune stimulation with antiviral suppression could achieve what neither approach accomplishes alone: actual resolution of chronic HBV infection.
How the study worked
Narrative review summarizing existing clinical trial data on thymosin α1 efficacy in hepatitis B, with a focus on combination therapy approaches using Tα1 alongside nucleoside/nucleotide analogs. The review reanalyzed previous Tα1 monotherapy trials in the context of modern combination therapy strategies.
Who was studied
Review covering patients with chronic hepatitis B infection
What this study cannot tell us
The combination therapy evidence cited comes from small studies, not large randomized trials. The review is somewhat advocacy-oriented, making the case for Tα1 combination therapy rather than providing a balanced assessment of all approaches. Clinical trials referenced were anticipated but results were not yet available at publication time. Individual patient response to Tα1 varies considerably.
How to read the evidence
This is a review article summarizing small studies and making a case for combination therapy. While the biological rationale is sound, the clinical evidence at publication was limited to small trials, with larger randomized studies still pending. The evidence grade reflects the promising but early-stage nature of the data.
When this study was published
Published in 2018, this review predates several years of subsequent research on HBV cure strategies. The combination therapy trials referenced may now have results available, and the HBV cure landscape has evolved with newer immunomodulatory approaches entering trials.
The bigger picture
The hepatitis B cure agenda has gained momentum in recent years, with researchers increasingly recognizing that antiviral suppression alone won't achieve functional cure — the immune system must be re-engaged. Thymosin α1 is one of several immunomodulatory approaches being explored alongside direct-acting antivirals, part of a broader shift toward combination strategies modeled on the successful hepatitis C cure revolution.
Questions still open
- Did the entecavir plus thymosin α1 clinical trials produce positive results, and if so, how do they compare to other combination approaches?
- Which patients with chronic hepatitis B are most likely to respond to thymosin α1 combination therapy?
- How does thymosin α1 compare to other immunomodulators like interferon in hepatitis B combination regimens?
Common questions
What is thymosin α1 and how does it fight hepatitis B?
Why can't current hepatitis B drugs cure the infection?
Read the original research
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach.
Journal of viral hepatitis, 25(1), 4-9
Citation
Naylor, P H; Mutchnick, M G. (2018). Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach.. Journal of viral hepatitis, 25(1), 4-9. https://doi.org/10.1111/jvh.12807